1
|
Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. Cell Rep Med 2023:101084. [PMID: 37315558 DOI: 10.1016/j.xcrm.2023.101084] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 03/21/2023] [Accepted: 05/21/2023] [Indexed: 06/16/2023]
Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed.
Collapse
Affiliation(s)
| | - Francesco M Fusco
- "D. Cotugno" Hospital, Azienda Specialistica dei Colli, Naples, Italy
| | | | - Silvio Borrè
- ASL Vercelli Malattie Infettive, Vercelli, Italy
| | - Sergio Carbonara
- U.O.C. Malattie Infettive - P.O.V. Emanuele II, Bisceglie (BT), Italy
| | - Sergio Lo Caputo
- Malattie infettive, Dipartimento di Scienze Mediche e Chirurgiche - A.O.U. Policlinico Foggia, Foggia, Italy
| | - Sebastiano Leone
- Division of Infectious Diseases, San Giuseppe Moscati Hospital, Avellino, Italy
| | - Giovanni Gori
- Centro di Farmacologia Clinica per la Sperimentazione dei Farmaci - Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - Paolo Maggi
- Università degli Studi della Campania Luigi Vanvitelli, Caserta, Italy
| | - Antonio Cascio
- Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
| | - Miriam Lichtner
- Department NESMOS Sapienza University of Rome, Infectious Disease Unit, SM Goretti Hospital, Latina, Italy
| | - Roberto Cauda
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | | | - Maria V Cossu
- I Divisione Malattie Infettive - ASST FBF SACCO, Milan, Italy
| | - Andrea Gori
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Silvia Roda
- U.O.C. Malattie Infettive - Fondazione IRCCS Policlinico San Matteo di Pavia, Viale Camillo Golgi, Italy
| | - Paola Confalonieri
- Struttura Complessa Pneumologia - Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy
| | - Stefano Bonora
- Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
| | - Gabriele Missale
- Department of Medicine and Surgery, University of Parma, Parma, Italy; Unit of Infectious Diseases and Hepatology - Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
| | - Mauro Codeluppi
- UOC di Malattie Infettive - Ospedale Guglielmo da Saliceto - AUSL Piacenza, Piacenza, Italy
| | - Ivano Mezzaroma
- UOC Malattie Infettive, AOU Policlinico Umberto 1, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
| | - Serena Capici
- Phase 1 Research Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - Emanuele Pontali
- Department of Infectious Diseases - E.O. Ospedali Galliera, Genova, Italy
| | - Marco Libanore
- Department Infectious Diseases, Arcispedale Sant'Anna - Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy
| | - Augusta Diani
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy
| | | | | | | | - Eva Piano Mortari
- B Cell Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy
| | | | | | | | | | | | | | - Rita Carsetti
- B Cell Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy
| | | | | |
Collapse
|
3
|
Amadasi S, Dal Zoppo S, Bonomini A, Bussi A, Pedroni P, Balestrieri G, Signorini L, Castelli F. A case of melioidosis probably acquired by inhalation of dusts during a helicopter flight in a healthy traveler returning from Singapore. J Travel Med 2015; 22:57-60. [PMID: 25183194 DOI: 10.1111/jtm.12150] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Revised: 04/08/2014] [Accepted: 04/15/2014] [Indexed: 12/01/2022]
Abstract
We present a case of melioidosis in an Italian male returning from Singapore after a short travel. He probably acquired the disease by inhalation, which is not the typical mode of transmission, in the absence of evident risk factors. The diagnosis was confirmed by real-time polymerase chain reaction of the culture while serology was useful to assess professional exposure among laboratory workers. Treatment consisted of an initial intensive phase with meropenem and trimethoprim-sulfamethaxazole (TMP-SMX), followed by 6 months of eradication therapy with TMP-SMX.
Collapse
Affiliation(s)
- Silvia Amadasi
- University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Matteelli A, Villani P, Carvalho ACC, El-Hamad I, Cusato M, Apostoli A, Marcantoni C, Calabresi A, Dal Zoppo S, Bigoni S, Regazzi M. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother 2012; 67:2470-3. [PMID: 22678727 DOI: 10.1093/jac/dks218] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES To evaluate the pharmacokinetic profile of ritonavir-boosted lopinavir in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. PATIENTS AND METHODS A longitudinal, cross-over pharmacokinetic evaluation of lopinavir with and without rifabutin in HIV-infected subjects with mycobacterial disease was done. All received lopinavir/ritonavir (400/100 mg twice a day) + an adjusted rifabutin dose of 150 mg every other day. Twelve-hour lopinavir pharmacokinetic sampling occurred at 2 weeks (T1) and 6 weeks (T2) after starting combined therapy and 10 weeks after completion of adjusted rifabutin (T3). Plasma was assayed using an HPLC method; lopinavir plasma concentration-time data were analysed using non-compartmental methods. RESULTS In 10 patients with complete lopinavir curves at T1, T2 and T3 pharmacokinetic values were, respectively: AUC(0-12), 187.5, 161.8 and 121.1 μg · h/mL; C(trough), 13.2, 10.0 and 7.7 μg/mL; C(max), 18.7, 15.9 and 13.3 μg/mL; and apparent oral clearance (CL/F), 0.035, 0.037 and 0.045 L/h/kg. Lopinavir C(trough) and AUC(0-12) were significantly higher at T1 compared with T3 while CL/F remained unchanged throughout. Combined treatment was well tolerated and none of the patients experienced moderate to severe lopinavir-related adverse events. CONCLUSIONS Lopinavir serum concentrations are not reduced when the drug is administered together with an adjusted dose of 150 mg of rifabutin every other day.
Collapse
Affiliation(s)
- Alberto Matteelli
- Institute of Infectious and Tropical Diseases, Brescia University Hospital, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|